Smoking Rates Hit Historic Low in US amid Pandemic

Mar.23.2022
Smoking Rates Hit Historic Low in US amid Pandemic
Smoking rates hit an all-time low in the US during the first year of the pandemic, attributed to public health campaigns and lifestyle changes.

According to foreign media reports on March 17, 2022, New York - in the first year of the COVID-19 pandemic, an increasing number of Americans have been abusing alcohol or using illegal drugs, but apparently not smoking.

 

According to survey data released on Thursday by the U.S. Centers for Disease Control and Prevention, smoking rates in the United States have reached a historic low in 2020, with only 1 in 8 adults reporting current use. The CDC also reported a decrease in adult e-cigarette usage.

 

Officials from the Disease Prevention and Control Center attributed this decline to public health campaigns and policies. However, outside experts suggest that increased prices for tobacco products and changes in lifestyle due to epidemics may have also played a role.

 

People who are mainly social smokers no longer have this situation," said Megan Roberts, a researcher at Ohio State University who focuses on tobacco product use among young people and adolescents.

 

More importantly, parents who suddenly had to stay home full-time with their children may have already cut back on expenses. Roberts also added that some individuals may have quit smoking after reports came out suggesting that smokers are more likely to develop severe illnesses if infected with COVID-19.

 

According to a report from the Centers for Disease Control and Prevention, based on a survey of over 31,000 American adults, 19% of Americans used at least one tobacco product in 2020, which is lower than the approximately 21% reported in 2019.

 

The use of cigars, smokeless tobacco, and pipes remain unchanged. Currently, the usage rate of electronic cigarettes has decreased from 4.5% in the previous year to 3.7%.

 

Cigarettes are the most commonly used tobacco product, with 12.5% of adults using them, which is lower than the 14% average.

 

For a long time, public health officials have believed that smoking - a risk factor for lung cancer, heart disease and stroke - is the leading cause of preventable deaths in the United States.

 

In 1965, 42% of American adults were smokers.

 

For several decades, this ratio has been gradually declining for various reasons, including taxes and smoking bans in workplaces and restaurants. However, some experts argue that a significant portion of the recent decline is due to the recent increase in prices.

 

For example, British American Tobacco - a company that produces brands such as Camel, Lucky Strike, and Newport - increased their prices fourfold in 2020, resulting in a total increase of around 50 cents per pack.

 

Interestingly, the amount of cigarettes sold in the United States actually increased in 2020, according to a report from the Federal Trade Commission. This is the first such growth in twenty years.

 

While there may be fewer smokers, those who do smoke tend to smoke more heavily.

 

This is a viable hypothesis - that people have more opportunities to smoke because they are not working," said David Sweanor, the global tobacco policy expert at the University of Ottawa.

 

He said that the investigation by the Disease Prevention and Control Center may also underestimate the number of smokers, either because some interviewees are dishonest or because the investigation missed too many smokers.

 

Other surveys have indicated that alcohol and illegal drug use have increased for many people during the first year of the pandemic.

 

(Source: Associated Press)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22